Serum IL-33 level is a predictor of progression-free survival after chemotherapy

This study aimed to evaluate the association between of serum IL-33 (sIL-33) level in gastric cancer (GC) patients and progression-free survival (PFS). A total of 62 patients with advanced GC and 32 healthy subjects were enrolled. sIL-33 level was detected in pre-chemotherapy patients, post-chemothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wenwei, Wu, Chen, Li, Xiaodong, Zheng, Zhuojun, Xie, Quanqin, Deng, Xu, Jiang, Jingting, Wu, Changping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471039/
https://www.ncbi.nlm.nih.gov/pubmed/28402273
http://dx.doi.org/10.18632/oncotarget.16627

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471039/
https://www.ncbi.nlm.nih.gov/pubmed/28402273
http://dx.doi.org/10.18632/oncotarget.16627

Ejemplares similares